oral glp 1 agonist With FDA approval of Wegovy pill, new era of GLP-1 weight loss drugs begins Current Insights, Advantages and Challenges

Conclusions GLP-1 RAs have emerged as novel agents in managing CVD, extending their utility beyond glycemic control in T2DM

[DOI] [PubMed] [Google Scholar] 249.Ahrn B., et al

Oral options typically carry lower manufacturing costs and eliminate the expenses associated with injection devices, cold chain shipping, and medical waste disposal

GLP-1a: Going beyond traditional use

Body weight loss percentage according to trial Estimated body weight loss percentage, normalised to 24 weeks More Speculative Peptide Drugs It suffices to say that anti-obesity drugs have undergone large gains in outcomes, larger average percentage decreases in weight and reductions in side-effects